Abstract 4947
Background
25-hydroxyvitamin D and active analogues have shown to inhibit growth of pancreatic cancer (PC) cell lines. However, studies describing the relationship between serum levels of vitamin D and survival in PC patients have shown conflicting results. The aim of the study was to evaluate the association between pre-treatment 25-hydroxyvitamin D levels and survival in Danish patients with PC.
Methods
In the prospective BIOPAC study (NCT03311776), the pre-treatment serum 25-hydroxyvitamin D (S-25(OH)D) concentrations were determined in 1233 patients with PC included from July 2008 to December 2018, using the DiaSorin Liaison 25-hydroxyvitamin D TOTAL assay. Age (median 67 years), gender (male/female: 675/558), BMI (<18.5/18.5-25/>25/unknown: 96/663/356/118), Performance status (PS) (0/1/2 + 3/unknown: 422/498/135/177) and stage (I+II/III+IV/unknown: 408/758/67) were retrieved. Survival was estimated in three S-25(OH)D groups as: insufficient <25 nmol/L, relatively insufficient 25-50 nmol/L and sufficient >50 nmol/L. For survival analysis, Kaplan-Meier plots, log-rank tests and the Cox regression model were used.
Results
Table:
699P
| Stage | I+II | III+IV | ||||
|---|---|---|---|---|---|---|
| S-25(OH)D levels | Pt, No. | mOS, months | 95%CI | Pt, No. | mOS, months | 95%CI |
| Sufficient | 205 | 26.2 | 21.2-34.1 | 383 | 7.2 | 6.2-8.1 |
| Relatively insufficient | 156 | 22.9 | 18.3-27.8 | 275 | 6.3 | 5.3-7.2 |
| Insufficient | 47 | 15.7 | 11.3-30.2 | 100 | 5.3 | 3.7-6.4 |
Abbreviations: Pt, No.: Patient number, mOS: median overall survival, CI: Confidence interval. Overall survival between the three S-25(OH)D groups in stages I and II, log rank p = 0.03, as well as in stages III and IV, log rank p = 0.02, were significantly different. In the multivariate Cox regression analysis, patients with sufficient S-25(OH)D levels had longer survival than those with insufficient levels (HR = 0.77, 95% CI 0.62-0.96; p = 0.02). PS 0 vs. 1 and vs. 2 + 3 (p < 0.01) and tumour stage I+II vs. III+IV (p < 0.01) were also associated with longer survival whereas age, gender and BMI were not.
Conclusions
Patients with PC and sufficient pre-treatment serum 25-hydroxyvitamin D levels had significantly longer OS than those with insufficient levels across all stages.
Clinical trial identification
NCT03311776.
Editorial acknowledgement
Legal entity responsible for the study
Julia Sidenius Johansen.
Funding
Axel Muusfeldt’s Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2551 - Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: an exploratory analysis of the GIM2 trial.
Presenter: Benedetta Conte
Session: Poster Display session 2
Resources:
Abstract
3426 - High dose Neo-adjuvant chemotherapy in Triple-Negative breast cancer with evidence of homologous recombination deficiency (HRD).
Presenter: Sonja Vliek
Session: Poster Display session 2
Resources:
Abstract
3792 - Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials
Presenter: Gustavo Werutsky
Session: Poster Display session 2
Resources:
Abstract
4044 - Estimating radiotherapy-induced cardiovascular mortality in female breast cancer patients.
Presenter: Mark De Ridder
Session: Poster Display session 2
Resources:
Abstract
719 - 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)
Presenter: Justin Stebbing
Session: Poster Display session 2
Resources:
Abstract
3595 - Adjuvant chemotherapy in elderly breast cancer patients: pattern of use and impact on overall survival
Presenter: Axel Berthelot
Session: Poster Display session 2
Resources:
Abstract
3992 - Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): a propensity score-matched study.
Presenter: Maria Vittoria Dieci
Session: Poster Display session 2
Resources:
Abstract
3477 - Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): an epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)
Presenter: Mellissa Williamson
Session: Poster Display session 2
Resources:
Abstract
3928 - Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study
Presenter: Hans Tesch
Session: Poster Display session 2
Resources:
Abstract
2184 - The clinical impact of adjuvant dose-dense sequential chemotherapy (dds-CT) in patients with high-risk operable breast cancer (BC); pooled analysis of 6 clinical trials.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract